As of 2024-12-13, the Intrinsic Value of Vifor Pharma AG (VIFN.SW) is
141.88 CHF. This VIFN.SW valuation is based on the model Discounted Cash Flows (Growth Exit 5Y).
With the current market price of 166.15 CHF, the upside of Vifor Pharma AG is
-14.60%.
The range of the Intrinsic Value is 82.04 - 855.63 CHF
141.88 CHF
Intrinsic Value
VIFN.SW Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
82.04 - 855.63 |
141.88 |
-14.6% |
| DCF (Growth 10y) |
117.32 - 1,215.06 |
202.63 |
22.0% |
| DCF (EBITDA 5y) |
83.29 - 148.28 |
113.25 |
-31.8% |
| DCF (EBITDA 10y) |
103.47 - 187.44 |
140.64 |
-15.4% |
| Fair Value |
55.63 - 55.63 |
55.63 |
-66.52% |
| P/E |
43.08 - 131.16 |
85.20 |
-48.7% |
| EV/EBITDA |
81.86 - 143.75 |
117.16 |
-29.5% |
| EPV |
62.75 - 92.06 |
77.41 |
-53.4% |
| DDM - Stable |
32.45 - 462.99 |
247.72 |
49.1% |
| DDM - Multi |
118.21 - 1,196.46 |
207.57 |
24.9% |
VIFN.SW Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
10,781.69 |
| Beta |
1.61 |
| Outstanding shares (mil) |
64.89 |
| Enterprise Value (mil) |
10,391.69 |
| Market risk premium |
5.10% |
| Cost of Equity |
5.62% |
| Cost of Debt |
4.25% |
| WACC |
5.52% |